Validation of HB-EGF and amphiregulin as targets for human cancer therapy

Fusanori Yotsumoto, Hiroshi Yagi, Satoshi O. Suzuki, Eiji Oki, Hiroshi Tsujioka, Touru Hachisuga, Kenzo Sonoda, Tatsuhiko Kawarabayashi, Eisuke Mekada, Shingo Miyamoto

研究成果: ジャーナルへの寄稿学術誌査読

123 被引用数 (Scopus)


Aberrant expression levels of epidermal growth factor receptor (EGFR) and its cognate ligands have been recognized as one of the causes of cancer progression. To investigate the validity of EGFR ligands as targets for cancer therapy, we examined the expression of EGFR ligands and in vitro anti-tumor effects of small interference RNA (siRNA) for EGFR ligands in various cancer cells. HB-EGF expression was dominantly elevated in ovarian, gastric, and breast cancer, melanoma and glioblastoma cells, whereas amphiregulin was primarily expressed in pancreatic, colon, and prostate cancer, renal cell carcinoma and cholangiocarcinoma cells. Transfection of siRNAs for HB-EGF or amphiregulin into these cells significantly increased the numbers of apoptotic cells with attenuation of EGFR and ERK activation. In lung cancer cells, any EGFR ligand was not recognized as a validated target for cancer therapy. These results suggest that HB-EGF and amphiregulin are promising targets for cancer therapy.

ジャーナルBiochemical and Biophysical Research Communications
出版ステータス出版済み - 1月 18 2008

!!!All Science Journal Classification (ASJC) codes

  • 生物理学
  • 生化学
  • 分子生物学
  • 細胞生物学


「Validation of HB-EGF and amphiregulin as targets for human cancer therapy」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。